We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Gives Soft ‘No’ to Janssen’s Leukemia Treatment, Rejects Roche’s Perjeta
The UK’s National Institute for Health and Care Excellence refused to recommend Janssen’s chronic lymphocytic leukemia treatment Imbruvica for reimbursement in June, but left the door open to further discussion.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor